Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

NCT02499835 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT02499835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02499835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 1/2
Overall status
Completed
Start date
July 1, 2015
Completion date
July 27, 2023
Enrollment
66 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hormone-resistant prostate cancer, metastatic malignant neoplasm in the bone, metastatic malignant neoplasm in the soft tissues, metastatic prostate carcinoma, prostate adenocarcinoma, recurrent prostate carcinoma, stage iv prostate cancer